Sutro Biopharma (Nasdaq: STRO) revealed on Thursday evening that its ongoing dose-escalation Phase 1 study of STRO-002 used to treat patients with ovarian cancer has shown encouraging interim results.
The dose-escalation study included 34 patients treated with clinically active dose levels. There were responses observed in 32% of evaluable patients treated, including one complete response, three confirmed partial responses and six unconfirmed partial responses.
The disease control rate at 12 weeks is 74% with 10 patients remaining on treatment.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“We are seeing improved outcomes in disease control and RECIST responses as the data matures and will continue to follow the patients who remain on study for further deepening of responses or clinical benefit,” said Dr Arturo Molina, Chief Medical Officer of Sutro.
The San Francisco based company said it is rapidly moving forward with further development of STRO-002 with dose expansion initiated to explore doses in less heavily pre-treated patients.
Sutro’s share price is up 23.53% so far in premarket trading, priced at $21, a record level for the stock.
PEOPLE WHO READ THIS ALSO VIEWED:
